-
Nov 18, 2024 | 
jacc.org | Subodh Verma |Scott Emerson |Jorge Plutzky |Steven Kahn
Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and ObesitySign in, Subscribe, or Pay to View
-
Aug 24, 2024 | 01498-3/fulltext?dgcid=twitter_organic_articles24_lancet&hss_channel=tw-27013292&sz=64)
thelancet.com | Maria Byrne |John Deanfield |Subodh Verma
Evidence before this studyHeart failure is more common in patients with overweight or obesity than in the general population and is typically heart failure with preserved ejection fraction, which has had few treatment options until recently.
-
Aug 12, 2024 | 
healio.com | Jill Rollet |Richard Smith |Subodh Verma
You've successfully added Diabetes in Endocrinology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Women with obesity and HF lost 9.6% of body weight with semaglutide vs. 7.2% for men. Men and women had similarly improved HF symptoms.
-
Aug 2, 2024 | 
jacc.org | Subodh Verma |Mark C. Petrie |Barry A. Borlaug |Javed Butler
References1. "Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets". Cardiovasc Res . 2023;118:3434-3450. 2. "Inflammatory mechanisms in heart failure with preserved ejection fraction". Physiology (Bethesda) . 2023;38:0. 3. "Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions". Cardiovasc Res . 2023;118:3536-3555. 4.
-
Jul 17, 2024 | 
mdpi.com | Subodh Verma |C. Mazer |Guillermo Agorrody |Isaac Begun
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Jun 24, 2024 | 
healio.com | Jill Rollet |Richard Smith |Subodh Verma
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Women with obesity and HF lost 9.6% of body weight with semaglutide vs. 7.2% for men. Men and women had similarly improved HF symptoms.
-
Apr 6, 2024 | 
jacc.org | Christopher M. Kramer |Milton Packer |Subodh Verma |A. Michael Lincoff
SUMMIT 2024: A Video Interview With Harlan Krumholz and Milton Packer Obesity Trials Collection at JACC SUMMIT SELECT STEP-HFpEF FLOW A Study of Tirzepatide in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity. Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity. Semaglutide Treatment Effect in People with Obesity and Heart Failure with Preserved Ejection Fraction.
-
Feb 12, 2024 | 
heart.bmj.com | Makoto Hibino |Subodh Verma |Craig M Jarret |Junichi Shimamura
AbstractObjective Aortic dissection and aortic aneurysm rupture are aortic emergencies and their clinical outcomes have improved over the past two decades; however, whether this has translated into lower mortality across countries remains an open question. The purpose of this study was to compare mortality trends from aortic dissection and rupture between the UK, Japan, the USA and Canada.
-
Jan 10, 2024 | 
inria.hal.science | Nitish K Dhingra |Subodh Verma |Javed Butler |Baylor Scott
Article Dans Une Revue JACC: Heart Failure Année : 2024 Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF Fichier principal 1-s2.0-S2213177923004535-main.pdf (959.7 Ko) Télécharger le fichier 1-s2.0-S2213177923004535-mmc1.pdf (583.92 Ko) Télécharger le fichier Origine : Fichiers éditeurs autorisés sur une archive ouverte hal-04384319 , version 1 (10-01-2024) Nitish K Dhingra, Subodh Verma, Javed Butler, Stefan D Anker, Joao Pedro Ferreira, et al.. Efficacy and...
-
Jan 1, 2024 | 
jacc.org | Nitish K Dhingra |Subodh Verma |Javed Butler |Stefan Anker
IntroductionIn patients with heart failure with reduced ejection fraction (HFrEF), the sodium glucose co-transporter 2 (SGLT2) inhibitors empagliflozin and dapagliflozin reduce the rates of cardiovascular (CV) death or heart failure (HF) hospitalization by about 25%.1-4 These benefits are observed independently of glycemic status5,6 and down to an eGFR of 20 mL/min/1.73 m2.
